Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment-Free Survival: A Novel Endpoint in Trials of Stereotactic Body Radiation With or Without Systemic Therapy.

International journal of radiation oncology, biology, physics·2026

Same author

EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.

The oncologist·2026

Same author

Castration Resistance Accelerates Prostate Cancer Kinetics.

The Prostate·2026

Same author

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Journal for immunotherapy of cancer·2026

Same author

Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Cancer·2026

Same author

The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer.

The oncologist·2026

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Evaluating immune responses after sipuleucel-T therapy.

Julius Strauss¹, Ravi A Madan, William D Figg

¹a Genitourinary Malignancies Branch ; Center for Cancer Research ; National Cancer Institute ; Bethesda , MD USA.

Cancer Biology & Therapy

|June 10, 2015

Summary

Sipuleucel-T shows promise for metastatic castration-resistant prostate cancer (mCRPC). Further research is needed to identify immune biomarkers that predict patient survival and clinical benefit from immunotherapy.

Keywords:

GU malignancies immune response prostate cancer sipuleucel-T urology

More Related Videos

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

Related Experiment Videos

Last Updated: Apr 11, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

Area of Science:

Immunology
Oncology
Prostate Cancer Research

Background:

Sipuleucel-T, approved in 2010, is used for metastatic castration-resistant prostate cancer (mCRPC).
Previous studies focused on sipuleucel-T's peripheral immune effects and retrospective survival associations.
A recent study by Fong et al. was the first to analyze sipuleucel-T's immune response within the tumor microenvironment.

Purpose of the Study:

To evaluate the predictive value of the peri-tumor immune response for patient survival.
To explore potential immune biomarkers for predicting clinical benefit in mCRPC patients treated with sipuleucel-T.
To address the limitations of radiographic or PSA progression as indicators of survival in immunotherapy.

Main Methods:

Characterization of the immune response within the tumor microenvironment following sipuleucel-T treatment.
Analysis of immune cell infiltration and activity in tumor samples.
Correlation of immune response metrics with patient survival data.

Main Results:

The Fong et al. study generated new hypotheses regarding the tumor microenvironment's immune response to sipuleucel-T.
Current data suggest that the peri-tumor immune response may not be a clear predictor of survival.
Radiographic or PSA progression may not accurately reflect outcomes for patients on sipuleucel-T or similar immunotherapies.

Conclusions:

There is a critical need to identify and prospectively validate immune biomarkers for sipuleucel-T.
Such biomarkers could serve as reliable indicators of clinical benefit and predict patient response.
Developing predictive immune biomarkers is essential for optimizing immunotherapy in mCRPC.